Idiopathic Short Stature – 2019 Pipeline Insight Study – ResearchAndMarkets.com

March 27, 2019 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Idiopathic
Short Stature – Pipeline Insight, 2019”
drug pipelines has been
added to ResearchAndMarkets.com’s offering.

The report offers comprehensive Insight of the pipeline (under
development) therapeutics scenario and growth prospects across
Idiopathic Short Stature development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental
Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.

Scope of the Report

  • The report provides a snapshot of the pipeline development for
    Idiopathic Short Stature
  • The report covers pipeline activity across the complete product
    development cycle i.e. clinical, pre-clinical and discovery stages for
    Idiopathic Short Stature
  • The report provides pipeline product profiles which includes product
    description, developmental activities, licensors & collaborators and
    chemical information
  • Provides pipeline assessment by monotherapy and combination therapy
    products, stage of development, route of administration, and molecule
    type for Idiopathic Short Stature
  • The report also covers the dormant and discontinued pipeline projects
    related to Idiopathic Short Stature

Reasons to Buy

  • Establish comprehensive understanding of the pipeline activity across
    this Idiopathic Short Stature to formulate effective R&D strategies
  • Gather information of the emerging competitors having potentially
    lucrative portfolio in this space and create effective counter
    strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target
    finding, drug repurposing, and precision medicine
  • Plot corrective measures for pipeline projects by understanding the
    pipeline depth and focus of Idiopathic Short Stature therapeutics
  • Devise in licensing and out licensing strategies by identifying
    prospective partners with the most attractive projects to enhance and
    expand business potential and scope
  • Modify the therapeutic portfolio by identifying inactive projects and
    understanding the factors that might have halted their progress

Key Topics Covered

1. Report Introduction

2. Idiopathic Short Stature Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Idiopathic Short Stature

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

  • Product Description
  • Research and Development
  • Product Development Activities

Companies Mentioned

  • Bolder Biotechnology
  • Braasch Biotech LLC
  • Dong-A Socio Group
  • LG Life Sciences
  • Myungmoon pharmaceutical Co.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/37rdwj/idiopathic_short?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Endocrine
and Metabolic Disorders Drugs